Phase 1b Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in Patients With End Stage Renal Disease Receiving Regular Hemodialysis
Latest Information Update: 08 Oct 2025
At a glance
- Drugs KN-060 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Alphamab Oncology
Most Recent Events
- 08 Oct 2025 New trial record